Crocin inhibit the metastasis of MDA-MB-231 cell line by suppressing epithelial to mesenchymal transition through WNT/β-catenin signalling pathway

Author:

Ghorbanzadeh Vajihe1,Hassan ALJAF Karwan Anwar2,Wasman Hunar Mustafa3,Dariushnejad Hassan45

Affiliation:

1. Cardiovascular Research Center, Shahid Rahimi Hospital

2. Medical Laboratory Analysis, Cihan University-sulaimaniya, Slemani

3. Medical Laboratory Science Department, University of Raparin, Kurdistan Region, Iraq

4. Razi Herbal Medicines Research Center

5. Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran

Abstract

Background: Triple-negative breast cancer has the poorest prognosis and survival rates compared to other breast cancer subtypes due to its invasive behaviours. This type of cancer does not respond to biological therapies and exhibits resistance to available treatment options. Therefore, it is imperative to discover new therapeutics to address this challenge. Methods: In this study, a TNBC cell line was utilized to investigate the anti-metastatic effect of crocin on the Wnt/β-catenin pathway. Cell proliferation was assessed using the MTT assay, and the effects of crocin on migration were monitored through transwell and wound healing experiments. The expression of specific epithelial-mesenchymal transition marker genes was evaluated using real-time polymerase chain reaction, and β-catenin expression was also examined through real-time polymerase chain reaction. Results: The findings revealed that crocin significantly inhibits cell proliferation and migration of tumour cells in a dose-dependent manner. Moreover, crocin decreased the expression of Vimentin, Snail, Zeb-1, and β-catenin. Additionally, crocin increased the expression of E-cadherin in the MDA-MB-231 cell line. Conclusions: The results demonstrated an association between crocin and the Wnt/β-catenin signalling pathway. In conclusion, this study establishes that crocin holds promise as a potential therapeutic option for triple-negative breast cancer.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference30 articles.

1. Patterns of better breast cancer care in countries with higher human development index and healthcare expenditure: Insights from GLOBOCAN 2020;Azadnajafabad;Front Public Health,2023

2. Development of targeted therapy therapeutics to sensitize triple-negative breast cancer chemosensitivity utilizing bacteriophage phi29 derived packaging RNA;Zhang;J Nanobiotechnol,2021

3. Triple-negative breast cancer: assessing the role of immunohistochemical biomarkers on neoadjuvant treatment;da Silva;Breast Cancer: Targets Ther,2021

4. Triple negative breast cancer: a review of present and future diagnostic modalities;Dass;Medicina,2021

5. Silibinin inhibit cell migration through downregulation of RAC1 gene expression in highly metastatic breast cancer cell line;Lashgarian;Drug Res,2020

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3